Short Interest in XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Declines By 55.2%

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) was the target of a large decrease in short interest in August. As of August 14th, there was short interest totaling 10,999 shares, a decrease of 55.2% from the July 30th total of 24,556 shares. Currently, 0.7% of the company’s shares are short sold. Based on an average trading volume of 5,965 shares, the days-to-cover ratio is currently 1.8 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of XTL Biopharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, XTL Biopharmaceuticals presently has a consensus rating of “Sell”.

XTL Biopharmaceuticals Stock Performance

XTLB stock opened at $2.47 on Friday. The firm has a 50 day simple moving average of $2.79 and a 200 day simple moving average of $2.73. XTL Biopharmaceuticals has a 52 week low of $2.01 and a 52 week high of $10.28. The stock has a market cap of $5.43 million, a P/E ratio of -3.86 and a beta of 1.46.

XTL Biopharmaceuticals (NASDAQ:XTLB) last released its quarterly earnings data on Tuesday, June 30th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. The business had revenue of ($0.26) million for the quarter.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.